Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.

@article{Bouvet2013ImpactOD,
  title={Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.},
  author={Emmanuelle Bouvet and C{\'e}cile Borel and Lucie Ob{\'e}ric and Gis{\`e}le Compaci and Bruno Cazin and Anne-Sophie Michallet and Guy Laurent and Lo{\"i}c Ysebaert},
  journal={Haematologica},
  year={2013},
  volume={98 1},
  pages={65-70}
}
Fludarabine-cyclophosphamide-rituximab is the most efficient first-line treatment for chronic lymphocytic leukemia patients. Many dose adjustments of the original MD Anderson Cancer Center regimen have been proposed. However, whether fludarabine-cyclophosphamide-rituximab relative dose intensity may have an impact on outcome has not yet been investigated. We retrospectively assessed relative dose intensity in 106 community-based patients included in our regional healthcare network from 2004-11… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

outcomes in patients with early breast cancer or aggressive lymphoma

  • G Compaci, L Ysebaert, L Obéric, H Derumeaux, G. Laurent
  • Crit Rev Oncol Hematol
  • 2011

Similar Papers

Loading similar papers…